REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

24/05/2017 15:06

RNS Number : 1090G
AstraZeneca PLC
24 May 2017
24 May 2017 15:00 BST
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 23 May 2017, it was notified by Mark Mallon, a Person Discharging Managerial Responsibilities of the Company, that, on 23 May 2017, Mr Mallon sold 20,000 American Depositary Shares (ADSs). Two ADSs are equivalent to one ordinary share of $0.25 in the Company.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
1 
Details of the person discharging managerial responsibilities / person closely associated 
a) 
Name 
Mark Mallon
2 
Reason for the notification 
a) 
Position/status 
Person Discharging Managerial Responsibilities
b) 
Initial notification /Amendment 
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
b) 
Nature of the transaction 
Sale of AstraZeneca PLC American Depositary Shares
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
US$ 33.900214 
20,000
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
23 May 2017
f) 
Place of the transaction 
NYSE
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Enquiries
Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, Neuroscience & Infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUSARRBVAVUAR